Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

    Kidney International Reports Date published:

  • VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis

    Journal of the American Society of Nephrology Date published:

  • Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

    Diabetes Care Date published:

  • The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system

    Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis Date published:

  • Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial

    International Journal of Cardiology Date published:

  • Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

    Kidney International Date published:

  • Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

    New England Journal of Medicine Date published:

  • Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)

    Journal of the American Society of Nephrology Date published:

  • Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet Date published:

  • The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

    Journal of the American Society of Nephrology Date published:

  • Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide

    European Heart Journal Date published:

  • Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

    Journal of the American Society of Nephrology Date published:

  • Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression

    Journal of the American Society of Nephrology Date published:

  • Targeting APRIL in the Treatment of IgA Nephropathy

    Clinical Journal of the American Society of Nephrology Date published:

  • Combination therapy with kidney protective therapies: optimizing the benefits?

    Current Opinion in Nephrology & Hypertension Date published: